Hilfinger Featured in Corporate Counsel about Connected Cars & Autonomous Vehicles Survey Results
02 November 2017
Partner Steve Hilfinger was featured in a Corporate Counsel article, “Interstate Regulatory Alignment: Keys to the Self-Driving Car?” about the results of Foley’s 2017 Connected Cars & Autonomous Vehicles Survey.
“Right now, some of the regulation is happening at the state level. Most of it has been in the way of testing, enabling on-road testing where you don’t necessarily have to have a driver if you satisfy the different requirements,” said Hilfinger. “It’d be very difficult to have a patchwork of 50 different state laws. I think you’re going to see some federalization and rulemaking by the [National Highway Traffic Safety Administration (NHTSA)].”
This story also ran in Legaltech News.
“Right now, some of the regulation is happening at the state level. Most of it has been in the way of testing, enabling on-road testing where you don’t necessarily have to have a driver if you satisfy the different requirements,” said Hilfinger. “It’d be very difficult to have a patchwork of 50 different state laws. I think you’re going to see some federalization and rulemaking by the [National Highway Traffic Safety Administration (NHTSA)].”
This story also ran in Legaltech News.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”